Abivax (ABVX) Research & Development (2022 - 2026)
Abivax (ABVX) posted quarterly Research & Development of -$58.0 million for Q1 2026, down 40.3% year-over-year from -$97.2 million in Q1 2025, and down 12.13% quarter-over-quarter from -$51.7 million in Q4 2025.
Abivax (ABVX) Research & Development (2022 - 2026) Analysis & Trends
Abivax's Research & Development history runs 5 years deep, the most recent figure standing at -$58.0 million for Q1 2026.
- In Q1 2026, Research & Development fell 40.3% year-over-year to -$58.0 million; the TTM figure through Mar 2026 stood at -$218.3 million (down 35.38% YoY), while the FY2025 annual figure was -$207.0 million, down 32.21% from the prior year.
- Research & Development for Q1 2026 stood at -$58.0 million, down from -$51.7 million in the prior quarter.
- The five-year high for Research & Development was -$49.28 in Q4 2022, with the low at -$64.8 million in Q3 2025.
- The 5-year median for Research & Development is -$41.3 million (2025), against an average of -$38.0 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development plunged 37113036.64% in 2024, then declined 6.46% in 2025.
- Abivax's Research & Development stood at -$49.28 in 2022, then plunged by 125.33% to -$111.04 in 2023, then slumped by 37113036.64% to -$41.2 million in 2024, then retreated by 25.52% to -$51.7 million in 2025, then retreated by 12.13% to -$58.0 million in 2026.
- Business Quant data shows ABVX's Research & Development at -$58.0 million in Q1 2026, -$51.7 million in Q4 2025, and -$64.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -58.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.00 Mn |
| Dec 31, 2025 | -51.73 Mn |
| Sep 30, 2025 | -64.78 Mn |
| Jun 30, 2025 | -43.74 Mn |
| Mar 31, 2025 | -41.34 Mn |
| Dec 31, 2024 | -41.21 Mn |
| Sep 30, 2024 | -47.54 Mn |
| Jun 30, 2024 | -31.13 Mn |
| Mar 31, 2024 | -38.83 Mn |
| Dec 31, 2023 | -111.04 |
| Dec 31, 2022 | -49.28 |